Table 1 Number of cases and adenovirus positivity rate for each disease
From: Whole genome-based surveillance for human adenovirus-related diseases in Kobe City, Japan, 2018–2022
Diagnosis | Year | Total | ||||
|---|---|---|---|---|---|---|
2018 | 2019 | 2020 | 2021 | 2022 | ||
Pharyngoconjunctival fever (PCF) | 26/39 (66.7%) | 37/47 (78.7%) | 1/1 (100%) | 1/1 (100%) | 2/2 (100%) | 67/90 (74.4%) |
Infectious gastroenteritis | 5/55 (9.1%) | 2/24 (8.3%) | 0/0 (0%) | 0/3 (0%) | 0/3 (0%) | 7/85 (8.2%) |
pneumonia | 0/4 (0%) | 1/1 (100%) | 0/0 (0%) | 0/0 (0%) | 0/1 (0%) | 1/6 (16.7%) |
epidemic keratoconjunctivitis (EKC) | 1/1 (100%) | 0/0 (0%) | 0/0 (0%) | 1/4 (25.0%) | 0/0 (0%) | 2/5 (40.0%) |
Herpangina | 2/17 (11.8%) | 0/17 (0%) | 0/1 (0%) | 0/0 (0%) | 0/3 (0%) | 2/38 (5.3%) |
Hand, Foot, and Mouth Disease (HFMD) | 0/80 (0%) | 1/94 (1.0%) | 0/4 (0%) | 0/11 (0%) | 0/6 (0%) | 1/195 (0.5%) |
Total | 34/196 (17.3%) | 41/183 (22.4%) | 1/6 (16.7%) | 2/19 (10.5%) | 2/15 (13.3%) | 80/419 (19.1%) |